Table 5.

Newly occurring or worsening grade 3/4 laboratory abnormalities (occurring in ≥5 % of evaluable patients)

Laboratory abnormality	n/N a (%)
Hematologic
Thrombocytopenia	6/58 (10.3)
Anemia	6/60 (10.0)
Neutropenia	4/58 (6.9)
Nonhematologic
Decreased serum phosphate	10/58 (17.2)
Increased serum lipase	9/53 (17.0)
Increased serum bilirubin (total)	8/60 (13.3)
Increased serum ALT	6/59 (10.2)
Decreased sodium	4/60 (6.7)
Hyperglycemia	3/56 (5.4)
Decreased serum albumin	3/58 (5.2)
Decreased potassium	3/60 (5.0)

AE adverse event, ALT alanine aminotransferase

^aPatients evaluable postbaseline who had <grade 4 at baseline